CoChat

Methylation of the DPYD Promoter: An Alternative Mechanism for Dihydropyrimidine Dehydrogenase Deficiency in Cancer Patients

Ezzeldin, Hany H., Lee, Adam M., Mattison, Lori K., Diasio, Robert B. · 2005 · Clinical Cancer Research

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Purpose: Dihydropyrimidine dehydrogenase (DPD) deficiency, a known pharmacogenetic syndrome associated with 5-fluorouracil (5-FU) toxicity, has been detected in 3% to 5% of the population. Genotypic studies have identified >32 sequence variants in the DPYD gene; however, in a number of cases, sequence variants could not explain the molecular basis of DPD deficiency. Recent studies in cell lines indicate that hypermethylation of the DPYD promoter might down-egulate DPD expression. The current study investigates the role of methylation in cancer patients with an unexplained molecular basis of DPD deficiency. Experimental Design: DPD deficiency was identified phenotypically by both enzyme assay and uracil breath test, and genotypically by denaturing high-performance liquid chromatography. The methylation status was evaluated in PCR products (209 bp) of bisulfite-modified DPYD promoter, using a novel denaturing high-performance liquid chromatography method that distinguishes between methylated and unmethylated alleles. Clinical samples included five volunteers with normal DPD enzyme activity, five DPD-deficient volunteers, and five DPD-deficient cancer patients with a history of 5-FU toxicity. Results: No evidence of methylation was detected in samples from volunteers with normal DPD. Methylation was detected in five of five DPD-deficient volunteers and in three of five of the DPD-deficient cancer patient samples. Of note, one of the two samples from patients with DPD-deficient cancer with no evidence of methylation had the mutation DPYD*2A, whereas the other had DPYD*13. Discussion: Methylation of the DPYD promoter region is associated with down-regulation of DPD activity in clinical samples and should be considered as a potentially important regulatory mechanism of DPD activity and basis for 5-FU toxicity in cancer patients.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-05-1520

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Cited by

See all 96

Metadata

Authors
Ezzeldin, H. H., Lee, A. M., Mattison, L. K., & Diasio, R. B.
Affiliations
University of Alabama at Birmingham (US)
Venue
Clinical Cancer Research
Published
2005-12-15
Volume
11
Issue
24
Pages
8699-8705
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2149894474
Cited by
96
References
26
Citations by year
2026: 2 · 2024: 2 · 2023: 1 · 2022: 6 · 2021: 4 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 3 · 2016: 3 · 2015: 5 · 2014: 5 · 2013: 6 · 2012: 5
FWCI
6.77
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Alabama at Birmingham
  • National Cancer Institute (CA-62164, CA85381, R01CA062164, R01CA085381)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Health Sciences › Medicine › Hematology › Methemoglobinemia and Tumor Lysis Syndrome
Keywords
dihydropyrimidine dehydrogenase deficiency, epigenetic silencing, 5-fluorouracil toxicity, pharmacogenetics, cancer patients, DPYD*2A, gene expression regulation
MeSH terms
Adult, Antimetabolites, Antineoplastic, Chromatography, High Pressure Liquid, Female, Fluorouracil, Genotype, Humans, Male, Middle Aged, Mutation, Neoplasms, Nucleic Acid Denaturation, Phenotype, Promoter Regions, Genetic, Down-Regulation, CpG Islands, DNA Methylation, Dihydrouracil Dehydrogenase (NADP), Dihydropyrimidine Dehydrogenase Deficiency

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Methylation of the DPYD Promoter: An Alternative Mechanism for Dihydropyrimidine Dehydrogenase Deficiency in Cancer Patients. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-1520
The paper
Ezzeldin, H. H., Lee, A. M., Mattison, L. K., & Diasio, R. B. (2005). Methylation of the DPYD Promoter: An Alternative Mechanism for Dihydropyrimidine Dehydrogenase Deficiency in Cancer Patients. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-1520

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.